自体干细胞/非干细胞治疗市场报告：2030 年趋势、预测与竞争分析

自体干细胞/非干细胞治疗的趋势和预测

至2030年，全球自体干细胞和非干细胞治疗市场预计将达到130亿美元，2024年至2030年的复合年增长率为10.2%。该市场的主要驱动力是对微创治疗的需求不断增长、干细胞和非干细胞治疗方法的快速技术进步以及政府对促进再生医学应用的支持不断增加。全球自体干细胞和非干细胞治疗市场的未来前景看好，医院和门诊手术中心市场充满机会。

• Lucintel 预测，由于癌症盛行率和治疗方法的扩大，以及自体干细胞治疗的使用不断增加，癌症和肿瘤学预计将在预测期内实现最高增长。
• 由于该地区慢性病患病率高、对微创手术的强劲需求以及有利的政府报销政策，预计北美地区在预测期内将出现最高的增长。

自体干细胞/非干细胞治疗市场新趋势

自体干细胞/非干细胞治疗市场的新兴趋势包括技术进步、监管变化和临床应用的变化。这些趋势将重塑再生医学的未来并确保市场成长。

• 强调个人化医疗：药物日益个人化是自体干细胞治疗市场日益强调个人化的一部分。透过患者的特定基因图谱实现的高度个人化在提高效率和减少副作用方面取得了重大成功。因此，这一趋势推动了更客製化的治疗，以改善患者的预后。
• 细胞处理技术的进步：新的细胞处理技术正在提高干细胞治疗的有效性。其技术力包括自动化细胞处理技术和细胞扩增方法，以获得更高品质和更多数量的治疗细胞。这无疑将进一步增加自体干细胞治疗的可行性和扩充性。
• 扩大临床应用：干细胞和非干细胞治疗方法的临床应用即将经历爆炸性增长。目前正在研究针对影响心血管系统、神经系统和整形外科疾病的疾病和损伤的新治疗方法。这加强了再生医学发展的基础，并继续为市场成长提供机会。
• 非干细胞疗法的开发：在开发不使用纯干细胞的治疗方法正在取得进展，例如组织工程和基因编辑。这些是再生医学的新方法，补充了使用干细胞的传统治疗方法。此类发明增加了治疗选择并推动市场成长。
• 监管发展和核准：由于监管机构的持续努力，该领域的进一步发展将继续推动新治疗方法的核准和商业化。简化监管流程以及增加对创新治疗方法的支持，将鼓励自体和非干细胞治疗方法的进一步开发和适应，实现更好的市场准入，并加快创新步伐。

新兴国家的这些趋势正在透过个人化医疗的进步、细胞处理技术的改进、临床应用的扩展、其他替代疗法的开发以及顺利的监管核准来推动自体干细胞和非干细胞治疗市场的发展。这促进了创新并持续提高再生医学的有效性。

自体干细胞/非干细胞治疗市场的最新趋势

自体和非干细胞治疗的关键发展代表了技术和临床的变化。这表明该研究领域是充满活力的，并且对健康的影响越来越大。

• 新治疗方法的核准FDA 等多个机构核准新的自体干细胞疗法，扩大了治疗范围，并为患有慢性疾病或损伤的患者提供了更多的治疗选择。其他活动包括心血管和自体免疫疾病的先进治疗，这是反映该领域进展的活跃领域。
• 细胞处理的创新：细胞处理的新技术包括自动化系统和扩增方法的改进，使干细胞治疗更加有效和强大。这些技术进步将促进高品质治疗细胞的产生并改善治疗的可及性。
• 非干细胞治疗方法的成长：预计组织工程和基因疗法等非干细胞疗法的市场也将显着成长。这些领域的新前沿正在开发各种再生医学方法，并补充基于干细胞应用的传统方法。
• 扩大研究和临床试验：增加自体和非干细胞疗法的研究和临床试验，开发新治疗方法，研究新应用，加深我们对治疗功效和安全性的理解也在取得进展。
• 个人化治疗的进步：该市场的主要趋势之一是根据患者情况创建个人化治疗。基于基因型和临床资讯的客製自订治疗正在透过走向个人化医疗来改善治疗结果并减少不利事件。

这些新增内容正在透过新的治疗方法、细胞处理技术、扩大的研究、临床试验和个人化治疗方法影响自体干细胞和非干细胞治疗市场。这是成长背后的驱动力，将再生医学推向更有效的水平。

自体干细胞/非干细胞治疗市场的策略性成长机会

随着技术的进步和应用的扩大，自体干细胞和非干细胞治疗市场的成长机会不断出现，塑造再生医学领域的未来并进一步扩大市场。

• 肿瘤治疗：此外，正在研究干细胞疗法用于癌症治疗和康復的肿瘤学领域代表着一个重大的成长机会。先进的细胞疗法和组织工程技术正在为各种癌症类型的管理和治疗提供新的治疗方法并不断增加市场潜力。
• 心血管应用：随着用于心臟修復和再生的干细胞疗法的发展，心血管应用仍然是主要成长领域之一。心血管疾病的细胞疗法透过满足未满足的需求并产生扩大治疗选择的创新来推动市场成长。
• 神经系统疾病：神经系统疾病的治疗被认为是一个新的成长机会。帕金森氏症和脊髓损伤是正在研究使用或不使用干细胞治疗的疾病的例子。这开闢了有效治疗的新途径，并扩大了市场应用的可能性。
• 整形外科创伤：另一个不断增长的领域是整形外科创伤和病症，其中干细胞疗法被考虑用于软骨修復和骨再生。再生医学的最新进展已开始为肌肉骨骼损伤提供新的解决方案，改善復健并促进市场成长。
• 糖尿病监测：即透过干细胞疗法管理糖尿病，包括胰岛素生成细胞的再生。使用糖尿病细胞的治疗创新正在开启糖尿病管理和改善患者治疗结果的新领域。

自体干细胞和非干细胞疗法的策略性成长机会是由肿瘤学、心血管应用、神经系统疾病、整形外科损伤和糖尿病管理相关的进步所推动的。这将扩大再生医学的范围并推动广泛治疗领域的创新。

自体干细胞/非干细胞治疗市场的驱动因素与挑战

主要的市场驱动因素和挑战正在塑造自体干细胞和非干细胞治疗市场的成长方向和趋势。在流动和成长要素中，技术进步、经济因素和监管考量对市场的塑造起着重要作用。

推动自体干细胞和非干细胞治疗市场的因素包括：

1.技术进步：影像处理、细胞处理和治疗技术的技术进步是促进市场成长的因素之一。自动化细胞处理和先进的基因编辑是最近的创新概念之一，它们提高了干细胞和非干细胞疗法的功效和效率，扩大了临床应用范围。

2.再生医学需求上升：再生医学需求上升是推动市场的主要因素之一。因此，患者和医疗保健提供者越来越需要慢性和退化性疾病的先进治疗方法，干细胞和非干细胞治疗正在被广泛采用。这将促进进一步的市场成长和创新。

3.临床应用的扩展：干细胞和非干细胞疗法临床应用的扩展正在推动这个市场。此外，针对癌症、心血管疾病和神经系统疾病等多种疾病的新治疗方法正在扩大再生医学的范围并增加市场机会。

4. 增加研发投资：增加研发投资将促进自体和非干细胞治疗市场的创新。这些资金来自公共和私营部门，支持创造和开发新的治疗方法和技术，以改善市场和增加竞争。

5. 监管支持和核准：新治疗方法的核准和商业化的明确监管途径、改善市场进入以及更快地推出新治疗方法。

自体干细胞/非干细胞治疗市场的挑战包括：

1. 监管障碍：克服复杂的监管要求并提供新的治疗方法以获得核准是很复杂的。此外，关于引入和采用干细胞和非干细胞新治疗方法的法规的地区差异极为严格。

2.开发成本高：高成本是先进治疗方法开发和製造过程中的主要挑战之一。这是由于与研究、开发和製造相关的成本，这可能会限制可用性和承受能力，特别是对于价格敏感的市场。为了广泛渗透市场，成本控制是绝对必要的。

3.伦理和安全问题：与使用干细胞的研究和治疗方法相关的伦理和安全问题被认为是最重要的问题之一。必须深入讨论知情同意、潜在风险和长期治疗结果等问题，以获得公众信任并获得监管部门的核准。

自体干细胞和非干细胞治疗市场的成长驱动因素是技术进步、再生医学需求的增加、临床应用的扩大、研发投资的增加和监管支持。主要瓶颈包括监管障碍、高昂的开发成本和道德问题。透过加强应对这些市场驱动因素和挑战，将实现更好的市场成长和创新。

自体干细胞/非干细胞分段治疗方法

本研究按产品类型、类型、应用、最终用途和地区对全球自体干细胞和非干细胞疗法进行了预测。

自体干细胞/非干细胞治疗市场的国家前景

近年来，由于技术创新和临床应用的推广，自体干细胞/非干细胞治疗市场得到了显着的发展。这些发生在美国、中国、德国、印度和日本，反映了再生医学的全球发展及其融入主流医疗系统。

• 美国：在美国，自体干细胞疗法已作为一种新治疗方法获得FDA批准并开始临床试验。该市场日益受到心血管和自体免疫疾病等多种适应症的个人化治疗的推动。细胞处理和保存技术的改进正在提高这些治疗方法的有效性和可及性。
• 中国：因此，中国在干细胞和非干细胞疗法方面都取得了进展，并且在临床研究和商业化方面正在经历快速增长。最近的趋势包括扩大干细胞银行服务以及增加再生医学相关研究的资金。中国研究机构正在利用先进的干细胞技术探索癌症和神经系统疾病的新治疗方法。
• 德国：然而，在将自体干细胞治疗纳入常规临床管理方面，德国是领先国家。最近的趋势包括针对整形外科和皮肤科疾病引入新的干细胞疗法。德国在实施治疗时非常重视品管和病人安全。
• 印度：由于医疗保健投资增加以及患者对更好医疗服务的需求，印度市场是干细胞和非干细胞治疗的新兴市场。最近，印度开发了利用干细胞治疗慢性疾病的先进疗法，并建立了专门从事再生医学的新研究设施。由于治疗费用负担较低，获得先进医疗保健的机会也在改善。
• 日本：日本在自体细胞和非干细胞治疗方面取得了可比较的进展。日本正在寻找新的应用，包括治疗与老龄化相关的退化性疾病。最近的发展包括用于治疗神经退化性疾病的细胞疗法的成功以及高效细胞收集和处理新技术的引入。

常问问题

Q.1 自体干细胞/非干细胞治疗的市场规模有多大？

A1. 到 2030 年，全球自体干细胞和非干细胞治疗市场预计将达到 130 亿美元。

Q.2 自体干细胞/非干细胞治疗市场的成长预测如何？

A2. 预计2024年至2030年全球自体干细胞/非干细胞治疗市场将以10.2%的复合年增长率成长。

Q.3 影响自体干细胞/非干细胞治疗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动力是对微创治疗的需求不断增长、干细胞和非干细胞治疗方法的快速技术进步以及政府为促进再生医学的使用而采取的支持措施不断增加。

Q4.市场的主要细分市场是：

A4. 自体干细胞和非干细胞治疗市场前景广阔，医院市场和门诊手术中心市场充满机会。

Q5.市场的主要企业是：

A5. 自体干细胞/非干细胞治疗的主要企业如下：

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• US Stem Cell

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测，由于癌症盛行率和治疗方法的扩大，以及自体干细胞治疗的使用不断增加，癌症和肿瘤学将在预测期内呈现最高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于慢性病的高盛行率、对微创手术的强劲需求以及该地区政府将提供有利的报销政策，预计北美地区将在预测期内出现最高的增长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球自体干细胞/非干细胞治疗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球自体干细胞/非干细胞治疗市场趋势（2018-2023）与预测（2024-2030）
• 按产品类型分類的自体干细胞和非干细胞治疗的全球市场
  • 血压监测装置
  • 肺压监测装置
  • 颅内压监测装置
• 自体干细胞/非干细胞治疗市场（按类型）
  • 自体干细胞
  • 自体非干细胞
• 按应用分類的自体干细胞/非干细胞治疗的全球市场
  • 神经退化性疾病
  • 自体免疫疾病
  • 癌症/肿瘤
  • 心血管疾病
• 按最终用途分類的全球自体干细胞和非干细胞治疗市场
  • 医院
  • 门诊手术中心
  • 其他的

第四章 2018-2030年区域市场趋势及预测分析

• 按地区分類的全球自体干细胞/非干细胞治疗市场
• 北美自体干细胞/非干细胞治疗市场
• 欧洲自体干细胞/非干细胞治疗市场
• 亚太地区自体干细胞/非干细胞治疗市场
• 其他地区自体干细胞/非干细胞治疗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按产品类型分類的全球自体干细胞和非干细胞治疗市场成长机会
  • 全球自体干细胞/非干细胞治疗市场的成长机会（按类型）
  • 全球自体干细胞/非干细胞治疗市场的成长机会（按应用）
  • 按最终用途分類的全球自体干细胞和非干细胞治疗市场的成长机会
  • 按地区分類的全球自体干细胞和非干细胞治疗市场成长机会
• 全球自体干细胞/非干细胞治疗市场新趋势
• 战略分析
  • 新产品开发
  • 扩大全球自体干细胞/非干细胞治疗市场的产能
  • 全球自体干细胞和非干细胞治疗市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业概况

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• US Stem Cell

Autologous Stem Cell and Non-Stem Cell Based Therapy Trends and Forecast

The future of the global autologous stem cell and non-stem cell based therapy market looks promising with opportunities in the hospital and ambulatory surgical center markets. The global autologous stem cell and non-stem cell based therapy market is expected to reach an estimated $13.0 billion by 2030 with a CAGR of 10.2% from 2024 to 2030. The major drivers for this market are growing demand for minimally invasive procedures, rapid technological advancements in stem cell and non-stem cell-based therapies, and rising supportive government initiatives to promote the use of regenerative medicine.

• Lucintel forecasts that cancer & tumor is expected to witness highest growth over the forecast period due to the rising use of autologous therapy along with the expanding incidence of cancer cases and treatments.
• North America is expected to witness highest growth over the forecast period due to the high prevalence of chronic diseases, existence of significant demand for minimally invasive procedures, and availability of favorable government reimbursement policies in the region.

Emerging Trends in the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Emerging trends in autologous stem cell- and non-stem cell-based therapy markets reveal evolving technology, changes in regulation, and changing clinical application. These are the trends that will reshape the future of regenerative medicine and ensure market growth.

• Greater Emphasis on Personalized Medicine: This increasing personalization of medicines is part of the growing emphasis in the autologous stem cell therapy market. The high level of personalization that has come through the particular genetic profile of the patient has gone a long way in providing increased efficiency with lesser side effects. This trend is, therefore, a push toward more customized therapies for better patient outcomes.
• Cell Processing Technology Advancement: Newer cell-processing technologies are increasing the effectiveness of stem cell treatments. The technological capabilities include automated cell processing and cell expansion methods that yield higher-quality and more numerous therapeutic cells. This will no doubt further enhance the feasibility and scalability of autologous stem cell treatments.
• Clinical Applications Expansion: Clinical applications for both stem cell and non-stem cell-based therapies are set for explosive growth. New treatments are being researched for diseases and injuries affecting the cardiovascular system, the nervous system, and orthopedic ailments. This continues to enhance the platform in which regenerative medicine is being developed while continuing to create more opportunities for market growth.
• Development of Non-Stem Cell Therapies: There has been progress in developing non-pure stem cell-based therapies, such as tissue engineering and gene editing. These represent other modes of regenerative medicine and supplementation of more traditional approaches to treatment that involve the use of stem cells. Such inventions improve the therapeutic options and drive market growth.
• Regulatory Advances and Approvals: Further development of the field through ongoing regulatory efforts will continue to facilitate approval and commercialization for new therapies. Streamlining regulatory processes, along with increased support for innovative treatments, will help further develop and adapt autologous stem cell and non-stem cell-based therapies, allowing better market access and forcing the pace of innovation.

These emerging trends are revolutionizing the autologous stem cell and non-stem cell-based therapy market by advancements in personalized medicine, improved cell processing technologies, expanded clinical uses, development of other alternatives, and smooth regulatory approvals. This, when put together, drives innovation and enhances the effectiveness of regenerative medicine continuously.

Recent Developments in the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Some of the key developments in autologous stem cell and non-stem cell-based therapies mark the change in technology and clinical practice. This thus denotes that the area of study is dynamic, with an increased impact on health.

• Approval of New Therapies: Adding new autologous stem cell therapies passed by the different bodies like the FDA has increased the scope of therapy and opened up treatment options for patients ailing from chronic diseases and injuries. Other areas include advanced treatments for cardiovascular conditions and autoimmune disorders, active areas reflecting ongoing progress in the field.
• Innovation in Cell Processing: New technologies for cell processing involve automated systems and improved expansion methodologies that make stem cell therapies more effective and powerful. Thus, these advances in the technology are promoting the generation of high-quality therapeutic cells and better access to treatments.
• Growth in Non-Stem Cell-Based Therapies: It is also estimated that the market is significantly growing in the non-stem cell based therapies such as tissue engineering and gene therapy. New frontiers in these fields have now opened up different approaches towards regenerative medicine and supplement traditional approaches based upon the application of stem cells.
• Expansion of Research and Clinical Trials: While research and clinical trials in both autologous stem cell and non-stem cell-based therapies have increased, the same growth brings about new therapies, investigates new applications, and refines the understanding of therapeutic efficacy and safety.
• Advancements in Personalized Treatment: One of the major developments in this market is the creation of treatments personalized to the patient profile. Custom therapies based on genotype and clinical information are improving treatment outcomes and reducing adverse events by moving toward individualized medicine.

These additions are affecting the autologous stem cell and non-stem cell-based therapy market in new therapies, technology of cell processing, expanded research, clinical trials, and personalized treatment approaches. This drives growth that is going to push regenerative medicine to another level of effectiveness.

Strategic Growth Opportunities for Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Growth opportunities in autologous stem cell and non-stem cell-based therapy markets continue to emerge with technological advancement and increasing applications, thus shaping the future in the area of regenerative medicine and further expanding markets.

• Oncology Treatments: Further, oncology represents a huge growth opportunity wherein the use of stem cell therapies is being explored for the treatment and recuperation of cancer. Newer treatment modalities are being offered by advanced cell therapy and tissue engineering techniques for the management and treatment of different types of cancer, along with increasing market potential.
• Cardiovascular Applications: Cardiovascular applications continue to be one of the major growth areas, and the development of stem cell therapies for repair and regeneration of the heart will also occur. Cell-based treatments for cardiovascular disease are producing innovations that are meeting unmet needs and extending treatment options, driving the market growth.
• Neurological Disorders: Treatment of neurological disorders may be considered an emerging growth opportunity. Parkinson's disease and spinal cord injuries are but two examples of medical conditions that are being studied with treatments both involving and not involving the use of stem cells. New avenues for effective treatments thus become available while the circles of market application are expanded.
• Orthopedic Traumas: Other growth areas include orthopaedic injuries and conditions, in which stem cell therapies are considered for the repair of cartilage and regeneration of bone. With recent advances made within regenerative medicine, new solutions have started to be provided to musculoskeletal injuries, improving recovery and contributing to the market growth.
• Monitoring of Diabetes: This, therefore, presents a very important growth opportunity: the management of diabetes with the use of stem cell therapies, including insulin-producing cell regeneration. Diabetes cell-based treatment innovations are opening new frontiers for the management of the disease and improvement of patients' outcomes.

The strategic growth opportunities in autologous stem cell and non-stem cell-based therapy markets are driven by advancements related to oncology, cardiovascular applications, neurological disorders, orthopaedic injuries, and diabetes management. This is a broadening the scope for regenerative medicine and driving innovation across wide therapeutic areas.

Autologous Stem Cell and Non-Stem Cell Based Therapy Market Driver and Challenges

Major drivers and challenges shape the direction of growth and development of the autologous stem cell and non-stem cell-based therapy market. In terms of flux or growth, technological advancement, economic factors, and regulatory considerations have played an influential role in shaping the market.

The factors responsible for driving the autologous stem cell and non-stem cell based therapy market include:

1. Technological Advances: Technological advancements in imaging, cell processing, and therapy techniques are amongst the factors contributing to the growth of the market. Automation of cell processing and advanced genetic editing are amongst the recent innovative concepts improving efficacy and efficiency in both stem cell and non-stem cell-based therapies, hence widening their clinical application scope.

2. Increasing Demand for Regenerative Medicine: The increasing demand for regenerative medicine is one of the major driving factors for the market. Therefore, patients and healthcare providers increasingly need therapies with advanced treatments for chronic and degenerative conditions, thereby fueling the wider adoption of both stem cell and non-stem cell-based therapies. This fosters further market growth and innovation.

3. Clinical Applications Expansion: But this is being driven by the expansion of clinical applications for both stem cell and non-stem cell-based therapies. Further, newer treatments for a range of disease conditions including cancer, cardiovascular diseases, and neurological disorders are expanding the scope of regenerative medicine and increasing market opportunities.

4. Growing Investment in Research and Development: Increased investment in research and development propels innovation into the autologous stem cell-and non-stem cell-based therapy market. This funding emanates from both the public and private sectors and supports the creation and development of new therapies and technologies that drive improvement and competitiveness in the market.

5. Regulatory Support and Approvals: These include support at the regulatory level by way of smooth approval processes: clearer pathways from regulatory bodies for the approval and commercialization of new therapies, better market access, and quickened introduction of new treatments.

Challenges in the autologous stem cell and non-stem cell based therapy market are:

1. Regulatory Hurdles: It is complicated to overcome complex regulatory requirements and make approvals possible by offering new kinds of therapies. The regional variations in regulations would also be very tough when it comes to high-stringency approval processes for the introduction and adoption of new stem cell and non-stem cell-based therapies.

2. High Development Costs: High cost is one of the major challenges in the development or manufacturing process of any advanced therapy. This may be due to costs related to research, development, and production, which could limit accessibility and affordability, especially for more price-sensitive markets. For wider access to the market, cost management becomes an absolute necessity for broader market penetration.

3. Ethical and Safety Issues: Ethical and safety issues with regards to research and therapies involving stem cells are considered some of the most major challenges. Issues of informed consent, risk potential, and long-term results have to be discussed in depth for winning public trust and gaining regulatory approval.

The growth drivers for the autologous stem cell and non-stem cell-based therapy market are technological advancements, increasing demand for regenerative medicine, increasing clinical applications, rising investment in R&D, and regulatory support. Major bottlenecks include regulatory hurdles, high development costs, and ethical issues. With more and more effort being put into addressing these drivers and challenges, better growth and innovation will be achieved in the market.

List of Autologous Stem Cell and Non-Stem Cell Based Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies autologous stem cell and non-stem cell based therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the autologous stem cell and non-stem cell based therapy companies profiled in this report include-

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Autologous Stem Cell and Non-Stem Cell Based Therapy by Segment

The study includes a forecast for the global autologous stem cell and non-stem cell based therapy by product type, type, application, end use, and region.

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type [Analysis by Value from 2018 to 2030]:

• Blood Pressure Monitoring Devices
• Pulmonary Pressure Monitoring Devices
• Intracranial Pressure Monitoring Devices

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type [Analysis by Value from 2018 to 2030]:

• Autologous Stem Cells
• Autologous Non-Stem Cells

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application [Analysis by Value from 2018 to 2030]:

• Neurodegenerative Disorders
• Autoimmune Diseases
• Cancer & Tumors
• Cardiovascular Diseases

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Ambulatory Surgical Centers
• Others

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

The autologous stem cell and non-stem cell-based therapy market has developed a lot in recent times owing to technological innovations and wider clinical applications. These are taking place in the United States, China, Germany, India, and Japan and reflect global developments in regenerative medicine and its incorporation into the mainstream health care system.

• United States: Within the United States, autologous stem cell therapy has seen new therapies currently approved by the FDA, while clinical trials have also been initiated to explore its other uses. The market is observing an upswing in personalized treatments for various indications, including cardiovascular diseases and autoimmune disorders. Improving technologies for cell processing and storage are serving to amplify the efficacy and access associated with these therapies.
• China: Thus, China has advanced in both the stem cell and non-stem cell-based therapies, putting much effort into rapid growth in both clinical research and commercialization. Development in recent times has been, among other things, the development of expanded services for stem cell banking and increased funding in research that relates to regenerative medicine. Chinese institutions explore new treatments for cancer and neurological disorders using advanced stem cell techniques.
• Germany: Nevertheless, Germany is the leader in terms of the integration of autologous stem cell therapies into everyday clinical management, with serious attention to regulatory compliance and, at the same time, effectively providing clinical efficacy. Recent developments in this country include the adoption of new stem cell-based treatments for orthopedic and dermatological conditions. Quality control and patient safety have been emphasized to a very high standard regarding the implementation of therapy in Germany.
• India: The Indian market is a developing market for both stem cell-based therapies and non-stem cell-based therapies, owing to increased investment in the health care and growing demand of patients for better health services. Recently, this country has developed advanced treatments using stem cells for chronic diseases and the establishment of new research facilities with special focus on regenerative medicine. Cost-friendly options for therapies increase access to advanced treatments.
• Japan: Japan has recorded equal progress in both autologous stem cell therapies and non-stem cell-based treatments. The country is looking toward new applications involving the treatment of age-related and degenerative diseases. Recent developments include success with cell therapy used for treating neurodegenerative disorders and new technologies introduced for efficient harvesting and processing of the cells.

Features of the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Market Size Estimates: Autologous stem cell and non-stem cell based therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Autologous stem cell and non-stem cell based therapy market size by various segments, such as by product type, type, application, end use, and region in terms of value ($B).

Regional Analysis: Autologous stem cell and non-stem cell based therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, types, applications, end uses, and regions for the autologous stem cell and non-stem cell based therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the autologous stem cell and non-stem cell based therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the autologous stem cell and non-stem cell based therapy market size?

Answer: The global autologous stem cell and non-stem cell based therapy market is expected to reach an estimated $13.0 billion by 2030.

Q.2 What is the growth forecast for autologous stem cell and non-stem cell based therapy market?

Answer: The global autologous stem cell and non-stem cell based therapy market is expected to grow with a CAGR of 10.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the autologous stem cell and non-stem cell based therapy market?

Answer: The major drivers for this market are growing demand for minimally invasive procedures, rapid technological advancements in stem cell and non-stem cell-based therapies, and rising supportive government initiatives to promote the use of regenerative medicine.

Q4. What are the major segments for autologous stem cell and non-stem cell based therapy market?

Answer: The future of the autologous stem cell and non-stem cell based therapy market looks promising with opportunities in the hospital and ambulatory surgical center markets.

Q5. Who are the key autologous stem cell and non-stem cell based therapy market companies?

Answer: Some of the key autologous stem cell and non-stem cell based therapy companies are as follows:

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Q6. Which autologous stem cell and non-stem cell based therapy market segment will be the largest in future?

Answer: Lucintel forecasts that cancer & tumor is expected to witness highest growth over the forecast period due to the rising use of autologous therapy along with the expanding incidence of cancer cases and treatments.

Q7. In autologous stem cell and non-stem cell based therapy market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the high prevalence of chronic diseases, existence of significant demand for minimally invasive procedures, and availability of favorable government reimbursement policies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the autologous stem cell and non-stem cell based therapy market by product type (blood pressure monitoring devices, pulmonary pressure monitoring devices, and intracranial pressure monitoring devices), type (autologous stem cells and autologous non-stem cells), application (neurodegenerative disorders, autoimmune diseases, cancer & tumors, and cardiovascular diseases), end use (hospitals, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type
  • 3.3.1: Blood Pressure Monitoring Devices
  • 3.3.2: Pulmonary Pressure Monitoring Devices
  • 3.3.3: Intracranial Pressure Monitoring Devices
• 3.4: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type
  • 3.4.1: Autologous Stem Cells
  • 3.4.2: Autologous Non-Stem Cells
• 3.5: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application
  • 3.5.1: Neurodegenerative Disorders
  • 3.5.2: Autoimmune Diseases
  • 3.5.3: Cancer & Tumors
  • 3.5.4: Cardiovascular Diseases
• 3.6: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Ambulatory Surgical Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region
• 4.2: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.2.1: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.2.2: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.3: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.3.1: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.3.2: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.4: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.4.1: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.4.2: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.5: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.5.1: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.5.2: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type
  • 6.1.3: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application
  • 6.1.4: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use
  • 6.1.5: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region
• 6.2: Emerging Trends in the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: BrainStorm Cell
• 7.2: Cytori Therapeutics
• 7.3: Dendreon Pharmaceuticals
• 7.4: Novartis
• 7.5: U.S. Stem Cell